Title: Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.
Journal: Clinical lung cancer 20110901
Title: Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110715
Title: Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110101
Title: Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100701
Title: Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100501
Title: Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.
Journal: European journal of cancer (Oxford, England : 1990) 20090901
Title: Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
Journal: Cancer chemotherapy and pharmacology 20080901
Title: The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.
Journal: Cancer chemotherapy and pharmacology 20080801
Title: Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.
Journal: British journal of cancer 20080520
Title: Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals.
Journal: Anti-cancer drugs 20080201
Title: The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401
Title: Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070301
Title: Effects of smoking on the pharmacokinetics of erlotinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20060401
Title: Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
Journal: Journal of clinical pharmacology 20060301
Title: Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050105
Title: Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030815
Title: Thappali SR, et al. Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation.Sci Pharm. 2012 Jul-Sep;80(3):633-46.